Adeno-associated Virus Formulations
Assignee4D Molecular Therapeutics Inc.
InventorsCATHERINE T. BARGLOW, JOHNNY C. GONZALES
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising adeno-associated virus (AAV) are provided herein. In some aspects, the pharmaceutical compositions comprise about 5 mM to about 20 mM Tris buffer, about 100 mM to about 250 mM sodium chloride, about 0.001% (w/v) to about 0.01% (w/v) Pluronic F68, and has a pH between 7.0 and 9.0. Methods of preparing a pharmaceutical composition comprising AAV, methods of treating a VEGF-associated disorder in a subject, and methods of storing AAV compositions are also provided.
Claims49
(canceled)
(canceled)
A pharmaceutical composition comprising adeno-associated virus (AAV) comprising a capsid of serotype 2 (AAV2) or a variant thereof and a buffering composition, said buffering composition comprising:
- (i) about 7 mM to about 12 mM of a Tris buffer;
- (ii) about 150 to about 200 mM of a pharmaceutically acceptable salt;
- and
- (iii) about 0.0005% (w/v) to about 0.01% (w/v) of a non-ionic surfactant;
- wherein the buffering composition has a pH above 7.0 and below about 8.5 and wherein the pharmaceutical composition does not comprise a divalent cation and does not comprise a sugar or sugar alcohol.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.